# New Line

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/new-line

- Industry: Agribusiness
- Headquarters: Weifang, China
- Website: www.newline.biz
- Latest round: Series A (Jul 27, 2026)
- Investors on record: 2

## About

New Line, based in Weifang, China, specializes in innovative feed additives that reduce antibiotic reliance in agriculture, focusing on bacteriophage solutions to enhance livestock health and productivity.Founded in 2018 in Weifang, China, Shandong New Line BIO INC. focuses on developing products that combat antibiotic resistance in farming. The company has engaged in one deal, with the most recent occurring on July 27, 2026. The founder's history is not specified, nor are any subsidiary relationships.Shandong New Line BIO INC. specializes in the research, development, production, and sale of innovative feed additives designed to reduce reliance on antibiotics in livestock and agriculture. The company's core product offerings revolve around bacteriophage-based solutions, effectively addressing the growing issue of antibiotic-resistant bacteria in animal husbandry and crop production. These products, developed in collaboration with leading agricultural and scientific institutions, aim to improve animal health and productivity while ensuring food safety. Primary end users include livestock farmers and agricultural producers seeking effective alternatives for disease management in farming operations. Shandong New Line BIO INC. primarily markets its products within China, with plans to expand its reach globally, responding to the increasing demand for sustainable agricultural practices.Shandong New Line BIO INC. operates on a business-to-business model, engaging directly with agricultural producers and livestock companies for sales transactions. The company's revenue generation is facilitated through the sale of its specialized bacteriophage products, structured as bulk orders or long-term supply agreements. Clients typically place orders based on specific needs for animal health interventions, focusing on promoting animal welfare and reducing antibiotic usage. The financial transactions are structured to support large-scale production and distribution, with pricing mechanisms aligned with the volume of product purchased. The company’s flagship products, developed through extensive research partnerships, form the cornerstone of its revenue-generating activities, catering to a market concerned with antibiotic resistance and sustainable farming practices.In July 2026, New Line raised an undisclosed amount of Series A funding led by CMB International Asset Management and Addor Capital. This funding will primarily be used for upgrading the drug-resistant bacteriophage library and expanding overseas business. The company aims to design and launch new products targeting specific market needs, with plans for geographic expansion into various overseas markets, enhancing their global footprint.

## Funding rounds

- Series A, Jul 27, 2026 — CMB International Asset Management, Addor Capital

## Investors

- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A